Management of Locally Advanced Pancreatic Cancer
| Autor: | Jin He, Robert W. Krell, Matthew J. Weiss, James C. Padussis, Georgios Gemenetzis, Massimo Falconi, Bradley N. Reames, Vincent P. Groot, Christopher L. Wolfgang, Sarah P. Thayer, Alex B. Blair, Chandrakanth Are |
|---|---|
| Přispěvatelé: | Reames, B. N., Blair, A. B., Krell, R. W., Groot, V. P., Gemenetzis, G., Padussis, J. C., Thayer, S. P., Falconi, M., Wolfgang, C. L., Weiss, M. J., Are, C., He, J. |
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
business.industry General surgery International survey MEDLINE Cancer Survey research medicine.disease locally advanced pancreas cancer Locally advanced pancreatic cancer 03 medical and health sciences 0302 clinical medicine medicine.anatomical_structure pancreas cancer pancreas surgery Current practice survey research 030220 oncology & carcinogenesis multidisciplinary management medicine 030211 gastroenterology & hepatology Surgery Pancreas surgery business Pancreas |
| Zdroj: | Annals of Surgery. 273:1173-1181 |
| ISSN: | 1528-1140 0003-4932 |
| Popis: | Objective: The aim of this study was to investigate surgeon preferences for the management of patients with locally advanced pancreatic cancer (LAPC). Background: Select patients with LAPC may become candidates for curative resection following neoadjuvant therapy, and recent reports of survival are encouraging. Yet the optimal management approach remains unclear. Methods: An extensive electronic survey was systematically distributed by email to an international cohort of pancreas surgeons. Data collected included practice characteristics, management preferences, attitudes regarding contraindications to surgery, and 6 clinical vignettes of patients that ultimately received a margin negative resection (with detailed videos of post-neoadjuvant imaging) to assess propensity for surgical exploration if resection status is not known. Results: A total of 153 eligible responses were received from 4 continents. Median duration of practice is 12 years (interquartile range 6-20) and 77% work in a university setting. Most surgeons (86%) are considered high volume (>10 resections/yr), 33% offer a minimally-invasive approach, and 50% offer arterial resections in select patients. Most (72%) always recommend neoadjuvant chemotherapy, and 65% prefer FOLFIRINOX. Preferences for the duration of chemotherapy varied widely: 39% prefer ≥2 months, 43% prefer ≥4 months, and 11% prefer ≥ 6 months. Forty-one percent frequently recommend neoadjuvant radiotherapy, and 53% prefer 5 to 6 weeks of chemoradiation. The proportion of surgeons favoring exploration following neoadjuvant varied extensively across 5 vignettes of LAPC, from 14% to 53%. In a vignette of oligometastatic liver metastases, 31% would offer exploration if a favorable therapy response is observed. Conclusions: In an international cohort of pancreas surgeons, there is substantial variation in management preferences, perceived contraindications to surgery, and the propensity to consider exploration in LAPC. These results emphasize the importance of a robust and nuanced multidisciplinary discussion for each patient, and suggest an evolving concept of "resectability." |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|